Brain+

Kort om Brain+

Brain+ är ett hälsoteknologibolag som utvecklar digitala terapier för att stödja kognitiv rehabilitering och mental hälsa. Bolagets lösningar kombinerar neurovetenskap, teknik och speldesign för att hjälpa personer med neurologiska sjukdomar som Alzheimers och andra kognitiva nedsättningar. Brain+ arbetar tillsammans med vårdgivare och forskningsinstitutioner för att integrera sina produkter i kliniska miljöer. Bolaget grundades 2012 och har sitt huvudkontor i Köpenhamn.

Kategori

Alla

Analysbevakning

Finvoices

Heta stolen

Rapportkommentar

2025-09-24

Brain+ Coverage Commentary - Launches first NHS pilot in UK primary care

Impala Nordic comments the news that Brain+ has signed an agreement to deploy the Company’s Cognitive Stimulation Therapy (“CST”) Assistant, Ayla, in one of the UK’s largest primary care practices within the UK National Health Service (“NHS”). We view this agreement as a landmark step for Ayla’s UK adoption.

Läs mer

2025-09-03

Brain+ - Strategy on track, revenue defers into 2026

Impala Nordic comments on the half-year report for H1 2025. The report is broadly in line with expectations, showing continued progress in UK private care homes. The company maintains its target of operational cash-flow break-even by mid-2026 and expects to achieve at least DKK 3.6m in contracted sales.

However, the expected realized cash flow from sales in 2025 has been adjusted to DKK 3.0m due to longer cycles from contracting to invoicing. On 2 September 2025, Brain+ expanded its agreement with Southcare to include three additional homes, further strengthening scalability in the UK, which we consider central to the investment case.

Läs mer

2025-06-25

Impala Nordic publishes equity analysis on Brain+ A/S

Impala Nordic initiates coverage on Brain+, a Danish life-science company pioneering digital solutions for improved dementia care, helping people affected by dementia live better lives.

The Company is developing Ayla, the world’s first dementia-care platform, aiming to reach operational break-even by mid 2026.

Läs mer

2025-05-27

FinVoices: Devika Wood, CEO at Brain+ A/S

In this episode, Brain+’s newly appointed CEO Devika Woods shares her background in digital health and her vision for the company’s potential.

She explains how the Ayla platform delivers Cognitive Stimulation Therapy to improve memory and attention, and discusses the UK healthcare system and efforts to integrate Brain+’s CST solution.

Läs mer

Lyssna på poddavsnitt

2025-03-26

Impala Nordic initierar analysbevakning på Brain+ A/S och inleder med en teaser.

Brain+ is a Danish health tech company transforming dementia care by enabling scalable, high-quality solutions for health and care providers.

The Company is developing Ayla, the world’s first dementia care platform for the scalable delivery of Cognitive Stimulation Therapy (CST), the leading non-pharmacological therapy for dementia.

Läs mer

Läs analysbevakning

2025-03-17

Heta Stolen - Brain+

We have interviewed Kim Baden-Kristensen, CEO of Brain+. Kim shares insights into the company’s operations, strategy, and future outlook.

He also provides his perspective on the digital healthcare market and the key factors investors should keep an eye on in the coming years.

Läs mer

Läs intervju